5HB.F Shanghai Haohai Biological Technology Co. Ltd
- Market cap
- EUR 394M
- P/E
- 22.0x
- P/B
- 0.56x
- ROE
- 4.6%
- Dividend yield
- 6.27%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 5HB.F undervalued?
Graham number5HB.F trades 26.2% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Haohai Biological Technology Co. Ltd fundamental analysis
No fundamental analysis for Shanghai Haohai Biological Technology Co. Ltd yet.
Shanghai Haohai Biological Technology Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Haohai Biological Technology Co. Ltd
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally. The company offers ophthalmic implants, assistive devices, and medical devices; medical optical instruments, including intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, and other ophthalmic medical products; hyaluronic acid and chitosan; and electronic in…
Full company profileShanghai Haohai Biological Technology Co. Ltd financial statements
Shanghai Haohai Biological Technology Co. Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 851M | 1.34B | 1.55B | 1.60B | 1.32B | 1.75B | 2.10B | 2.63B | 2.68B | 2.45B |
| Gross Profit | 710M | 1.06B | 1.21B | 1.23B | 990M | 1.26B | 1.45B | 1.85B | 1.87B | 1.71B |
| Operating Income | 310M | 416M | 443M | 302M | 125M | 228M | 220M | 438M | 446M | 317M |
| EBITDA | - | 532M | 611M | 554M | 262M | 388M | 448M | 713M | 689M | 465M |
| Net Income | 305M | 372M | 415M | 371M | 230M | 352M | 180M | 416M | 420M | 251M |
| EPS | - | 2.33 | 2.59 | 2.08 | 1.29 | 2.00 | 1.04 | 2.43 | 1.82 | 1.11 |
| Balance Sheet | ||||||||||
| Total Assets | 3.69B | 4.08B | 4.44B | 6.15B | 6.30B | 6.95B | 6.89B | 7.11B | 7.12B | 6.72B |
| Total Liabilities | 708M | 709M | 601M | 499M | 564M | 890M | 990M | 1.09B | 1.20B | 1.12B |
| Shareholders' Equity | 2.90B | 3.20B | 3.61B | 5.45B | 5.49B | 5.71B | 5.51B | 5.65B | 5.58B | 5.42B |
| Cash & Short-term Investments | 2.01B | 1.80B | 1.44B | 3.22B | 3.09B | 2.90B | 2.54B | 2.74B | 2.63B | 2.45B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 254M | 343M | 391M | 349M | 262M | 342M | 231M | 634M | 649M | 491M |
| Capital Expenditure | 75.7M | 134M | 151M | 249M | 190M | 271M | 309M | 343M | 363M | 187M |
| Free Cash Flow | - | 208M | 239M | -50.4M | 66.2M | 70.2M | -85.9M | 98.8M | 285M | 304M |
| Ratios | ||||||||||
| ROE | 10.5% | 11.6% | 11.5% | 6.8% | 4.2% | 6.2% | 3.3% | 7.4% | 7.5% | 4.6% |
| ROA | 8.3% | 9.1% | 9.3% | 6.0% | 3.7% | 5.1% | 2.6% | 5.9% | 5.9% | 3.7% |
| Net Profit Margin | 35.8% | 27.7% | 26.8% | 23.2% | 17.4% | 20.1% | 8.6% | 15.8% | 15.7% | 10.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shanghai Haohai Biological Technology Co. Ltd dividends
- Dividend yield
- 6.27%
- Forward dividend
- 0.11 EUR
- Payout ratio
- 91.1%
- Ex-dividend date
- Sep 4, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 229M | 1.01 | 91.1% |
| 2024 | CNY 260M | 1.13 | 61.8% |
| 2023 | CNY 76.3M | 0.45 | 18.3% |
| 2022 | CNY 122M | 0.70 | 67.5% |
| 2021 | CNY 87.9M | 0.50 | 25.0% |
| 2020 | CNY 124M | 0.70 | 53.9% |
| 2019 | EUR 80.0M | 0.45 | 21.6% |
| 2018 | EUR 80.0M | 0.50 | 19.3% |
| 2017 | EUR 85.8M | 0.54 | 23.0% |
| 2016 | EUR 58.6M | - | 19.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 14:10 on Jun 6, 2024.
Who owns Shanghai Haohai Biological Technology Co. Ltd
- Insiders 0.15%
- Institutions 7.86%
- Public & others 92.00%
- Shares outstanding 33.7M
- Free float 86.2M
Shanghai Haohai Biological Technology Co. Ltd company profile
- Company name
- Shanghai Haohai Biological Technology Co. Ltd
- Ticker
- 5HB.F
- ISIN
- CNE100001W69
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,110
- Fiscal year end
- December
- Address
- Wenguang Building, Shanghai, China, 200336
- Phone
- 86 21 5229 3555
- Website
- 3healthcare.com
About Shanghai Haohai Biological Technology Co. Ltd
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally. The company offers ophthalmic implants, assistive devices, and medical devices; medical optical instruments, including intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, and other ophthalmic medical products; hyaluronic acid and chitosan; and electronic instruments, such as semiconductors, optoelectronics, lasers, radio frequency, and ultrasonic instruments. It also engages in the research and development of biological engineering and pharmaceutical products and related technology transfer activities, consulting, and other services; research, development, production, and sales of radio frequency instruments; cell technology and biochemical product technology research and development; computer, communication, and other electronic equipment manufacturing; instrument manufacturing; manufacture and sale of biological reagents, biological agents, and biological materials; medical-grade sodium hyaluronate bio-based skincare products; intraocular lens and related products; intraocular lens injectors and materials, equipment, chemical products, and accessories for contact lenses and artificial lenses; sale of ophthalmology products; and provision of other machines and accessories. In addition, the company is involved in property management; business management consulting; non-residential real estate leasing; provision of technical services, technology promotion, development and transfer, technical consulting and exchange; wholesale of cosmetics; import and export of goods; import and export of technology; and information technology consulting services. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. The company was founded in 2007 and is headquartered in Shanghai, China.
Shanghai Haohai Biological Technology Co. Ltd management
5- Dr. Jianying WuGM & Chairman · born 1964
- Mr. Minjie Tang CPACFO & Executive Director · born 1975
- Ms. Yiyi ChenExecutive Director · born 1982
- Ms. Min TianJoint Company Secretary · born 1989
- Ms. Ying Tung LaiJoint Company Secretary